Fideuram Intesa Sanpaolo Private Banking S.P.A. Makes New $3.32 Million Investment in Biogen Inc. $BIIB

Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 18,873 shares of the biotechnology company’s stock, valued at approximately $3,321,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BIIB. WPG Advisers LLC increased its position in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC grew its holdings in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares during the period. First Horizon Corp acquired a new stake in shares of Biogen in the 4th quarter worth approximately $30,000. WFA of San Diego LLC acquired a new stake in shares of Biogen in the 2nd quarter worth approximately $32,000. Finally, GoalVest Advisory LLC acquired a new stake in shares of Biogen in the 4th quarter worth approximately $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BIIB. Tudor Pickering set a $201.00 price target on Biogen in a report on Monday, February 9th. Weiss Ratings upgraded Biogen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Rothschild & Co Redburn upped their price target on Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Wells Fargo & Company upped their price target on Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Sunday, February 8th. Finally, HSBC upped their price target on Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen Price Performance

BIIB stock opened at $187.80 on Thursday. Biogen Inc. has a 1 year low of $121.05 and a 1 year high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock’s 50 day moving average price is $185.39 and its 200 day moving average price is $180.41. The firm has a market cap of $27.73 billion, a P/E ratio of 20.15, a PEG ratio of 1.68 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the company earned $3.02 EPS. Biogen’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, sell-side analysts expect that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.